Photo taken from mskcc.org
Dec 7, 2023, 03:21
Dana responded well to the experimental drug nirogacestat for her desmoid tumor – Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center shared on their LinkedIn:
“ICYMI: On November 27, the U.S. Food and Drug Administration approved nirogacestat (Ogsiveo™) for adults with desmoid tumors that cannot be treated with surgery alone. The approval was based on research led by investigators at MSK. Nirogacestat is the first targeted therapy ever to be approved for desmoid tumors.
Dana, shown here with her husband, John, has responded well to the experimental drug nirogacestat for her desmoid tumor. Learn more about her care from MSK’s sarcoma expert Mrinal Gounder here. ”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 12:48
Apr 1, 2025, 12:16
Apr 1, 2025, 12:13
Apr 1, 2025, 12:07
Apr 1, 2025, 11:53